Musculoskeletal solutions company has signed an agreement to acquire spine technology firm in an
According to the terms of the deal, shareholders of NuVasive will secure 0.75 of a share of Globus Medical Class A common stock for each owned share of NuVasive common stock after the closure of the transaction.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Upon completion of the deal, Globus Medical shareholders will hold a stake of around 72% in the combined company, on a completely dilutive basis, while NuVasive shareholders will own the remaining 28% interest.
NuVasive CEO Chris Barry said: “Together, we will be able to offer an exceptional portfolio of clinically proven solutions, supported by strong commercial and surgeon education teams.鈥�
Generating more than聽$1bn in net sales, NuVasive offers less-invasive and procedurally integrated surgical solutions.
Established in 2003 and based in Audubon, Pennsylvania, US, Globus Medical is engaged in the development of products for patients with musculoskeletal disorders.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataWith more than 5,000 employees, the entities will now share operations in over 50 countries.
The deal is expected to help boost both of the firm鈥檚 globalisation strategies and target the $50bn musculoskeletal market.
Globus Medical president and CEO Dan Scavilla said: “This transaction reflects our mission to become the leading musculoskeletal technology company in the world by developing products that promote healing in patients with musculoskeletal disorders.鈥�
Subject to the approval of both company’s shareholders, regulatory approval and other customary closing conditions, the deal is expected to be completed in the middle of the year.
Once the deal concludes, the combined firm will consist of an 11-member board, including eight directors from Globus Medical’s board and three directors from NuVasive’s board.
